This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hudziak, R M Articles by Ullrich, A Search for Related Content PubMed PubMed Citation Articles by Hudziak, R M Articles by Ullrich, A

 Previous Article  |  Next Article 

Mol Cell Biol. 1989 March; 9(3): 1165-1172

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Department of Developmental Biology, Genentech, Inc., South San Francisco, California 94080.

ABSTRACT

The HER2/c-erbB-2 gene encodes the epidermal growth factor receptorlike human homolog of the rat neu oncogene. Amplification of this gene in primary breast carcinomas has been show to correlate with poor clinical prognosis for certain cancer patients. We show here that a monoclonal antibody directed against the extracellular domain of p185HER2 specifically inhibits the growth of breast tumor-derived cell lines overexpressing the HER2/c-erbB-2 gene product and prevents HER2/c-erbB-2-transformed NIH 3T3 cells from forming colonies in soft agar. Furthermore, resistance to the cytotoxic effect of tumor necrosis factor alpha, which has been shown to be a consequence of HER2/c-erbB-2 overexpression, is significantly reduced in the presence of this antibody.

This article has been cited by other articles:

• Chu, Q. S.C., Cianfrocca, M. E., Goldstein, L. J., Gale, M., Murray, N., Loftiss, J., Arya, N., Koch, K. M., Pandite, L., Fleming, R. A., Paul, E., Rowinsky, E. K. (2008). A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer. Clin. Cancer Res. 14: 4484-4490 [Abstract] [Full Text]  
• Dahabreh, I. J., Linardou, H., Siannis, F., Fountzilas, G., Murray, S. (2008). Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. The Oncologist 13: 620-630 [Abstract] [Full Text]  
• Sachdev, D., Yee, D. (2008). Disrupting Insulin-Like Growth Factor Signaling as a Potential Cancer Therapy. aacredbook 2008: 39-58 [Abstract] [Full Text]  
• Hynes, N. E (2008). ErbB Receptors in Cancer: HER2/ErbB2 as a Therapeutic Target. aacredbook 2008: 123-130 [Abstract] [Full Text]  
• Burris, H. III, Rocha-Lima, C. (2008). New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways. The Oncologist 13: 289-298 [Abstract] [Full Text]  
• Emanuel, S. L., Hughes, T. V., Adams, M., Rugg, C. A., Fuentes-Pesquera, A., Connolly, P. J., Pandey, N., Moreno-Mazza, S., Butler, J., Borowski, V., Middleton, S. A., Gruninger, R. H., Story, J. R., Napier, C., Hollister, B., Greenberger, L. M. (2008). Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors. Mol. Pharmacol. 73: 338-348 [Abstract] [Full Text]  
• Bird, B. R.J. H., Swain, S. M. (2008). Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems. Clin. Cancer Res. 14: 14-24 [Abstract] [Full Text]  
• Sharma, S. V., Settleman, J. (2007). Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21: 3214-3231 [Abstract] [Full Text]  
• Stavenhagen, J. B., Gorlatov, S., Tuaillon, N., Rankin, C. T., Li, H., Burke, S., Huang, L., Johnson, S., Bonvini, E., Koenig, S. (2007). Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fc{gamma} Receptors. Cancer Res. 67: 8882-8890 [Abstract] [Full Text]  
• Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., Arteaga, C. L. (2007). Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network. Clin. Cancer Res. 13: 4909-4919 [Abstract] [Full Text]  
• Barok, M., Isola, J., Palyi-Krekk, Z., Nagy, P., Juhasz, I., Vereb, G., Kauraniemi, P., Kapanen, A., Tanner, M., Vereb, G., Szollosi, J. (2007). Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Molecular Cancer Therapeutics 6: 2065-2072 [Abstract] [Full Text]  
• Garrett, J. T., Rawale, S., Allen, S. D., Phillips, G., Forni, G., Morris, J. C., Kaumaya, P. T. P. (2007). Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu. J. Immunol. 178: 7120-7131 [Abstract] [Full Text]  
• Kim, H., Yoo, T., Park, D., Park, J., Cho, Y., Sohn, C., Jeon, W., Kim, B., Kim, M., Chae, S., Sohn, J. (2007). Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients. Ann Oncol 18: 892-897 [Abstract] [Full Text]  
• Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., Baselga, J. (2007). Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. JNCI J Natl Cancer Inst 99: 628-638 [Abstract] [Full Text]  
• Sachdev, D., Yee, D. (2007). Disrupting insulin-like growth factor signaling as a potential cancer therapy. Molecular Cancer Therapeutics 6: 1-12 [Abstract] [Full Text]  
• Wehrman, T. S., Raab, W. J., Casipit, C. L., Doyonnas, R., Pomerantz, J. H., Blau, H. M. (2006). A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Proc. Natl. Acad. Sci. USA 103: 19063-19068 [Abstract] [Full Text]  
• Cardoso, F., Durbecq, V., Laes, J.-F., Badran, B., Lagneaux, L., Bex, F., Desmedt, C., Willard-Gallo, K., Ross, J. S., Burny, A., Piccart, M., Sotiriou, C. (2006). Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. Molecular Cancer Therapeutics 5: 3042-3051 [Abstract] [Full Text]  
• Meric-Bernstam, F., Hung, M.-C. (2006). Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.. Clin. Cancer Res. 12: 6326-6330 [Abstract] [Full Text]  
• Krag, D. N., Shukla, G. S., Shen, G.-P., Pero, S., Ashikaga, T., Fuller, S., Weaver, D. L., Burdette-Radoux, S., Thomas, C. (2006). Selection of Tumor-binding Ligands in Cancer Patients with Phage Display Libraries.. Cancer Res. 66: 7724-7733 [Abstract] [Full Text]  
• Menotti, L., Cerretani, A., Campadelli-Fiume, G. (2006). A Herpes Simplex Virus Recombinant That Exhibits a Single-Chain Antibody to HER2/neu Enters Cells through the Mammary Tumor Receptor, Independently of the gD Receptors.. J. Virol. 80: 5531-5539 [Abstract] [Full Text]  
• Vajkoczy, P., Knyazev, P., Kunkel, A., Capelle, H.-H., Behrndt, S., von Tengg-Kobligk, H., Kiessling, F., Eichelsbacher, U., Essig, M., Read, T.-A., Erber, R., Ullrich, A. (2006). Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc. Natl. Acad. Sci. USA 103: 5799-5804 [Abstract] [Full Text]  
• Huang, T.-H., Morrison, S. L. (2006). A Trimeric Anti-HER2/neu ScFv and Tumor Necrosis Factor-{alpha} Fusion Protein Induces HER2/neu Signaling and Facilitates Repair of Injured Epithelia. J. Pharmacol. Exp. Ther. 316: 983-991 [Abstract] [Full Text]  
• Guthridge, M. A., Goodall, G. J., Pitson, S. M. (2006). Meeting Report: Barossa 2005--Signaling Networks. Sci Signal 2006: pe9-pe9 [Abstract] [Full Text]  
• Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., Cameron, D., Dowsett, M., Barrios, C. H., Steger, G., Huang, C.-S., Andersson, M., Inbar, M., Lichinitser, M., Lang, I., Nitz, U., Iwata, H., Thomssen, C., Lohrisch, C., Suter, T. M., Ruschoff, J., Suto, T., Greatorex, V., Ward, C., Straehle, C., McFadden, E., Dolci, M. S., Gelber, R. D., the Herceptin Adjuvant (HERA) Trial Study Team, (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.. NEJM 353: 1659-1672 [Abstract] [Full Text]  
• Burris, H. A. III, Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K. L., O'Neil, B., Marcom, P. K., Ellis, M. J., Overmoyer, B., Jones, S. F., Harris, J. L., Smith, D. A., Koch, K. M., Stead, A., Mangum, S., Spector, N. L. (2005). Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas. JCO 23: 5305-5313 [Abstract] [Full Text]  
• Giaccone, G. (2005). HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol 16: 538-548 [Abstract] [Full Text]  
• Wagner, S., Hafner, C., Allwardt, D., Jasinska, J., Ferrone, S., Zielinski, C. C., Scheiner, O., Wiedermann, U., Pehamberger, H., Breiteneder, H. (2005). Vaccination with a Human High Molecular Weight Melanoma-Associated Antigen Mimotope Induces a Humoral Response Inhibiting Melanoma Cell Growth In Vitro. J. Immunol. 174: 976-982 [Abstract] [Full Text]  
• Carter, P., Smith, L., Ryan, M. (2004). Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 11: 659-687 [Abstract] [Full Text]  
• Tanner, M., Kapanen, A. I., Junttila, T., Raheem, O., Grenman, S., Elo, J., Elenius, K., Isola, J. (2004). Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Molecular Cancer Therapeutics 3: 1585-1592 [Abstract] [Full Text]  
• Austin, C. D., De Maziere, A. M., Pisacane, P. I., van Dijk, S. M., Eigenbrot, C., Sliwkowski, M. X., Klumperman, J., Scheller, R. H. (2004). Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin. Mol. Biol. Cell 15: 5268-5282 [Abstract] [Full Text]  
• Osborne, C., Wilson, P., Tripathy, D. (2004). Oncogenes and Tumor Suppressor Genes in Breast Cancer: Potential Diagnostic and Therapeutic Applications. The Oncologist 9: 361-377 [Abstract] [Full Text]  
• Sundaram, R., Lynch, M. P., Rawale, S. V., Sun, Y., Kazanji, M., Kaumaya, P. T. P. (2004). De Novo Design of Peptide Immunogens That Mimic the Coiled Coil Region of Human T-cell Leukemia Virus Type-1 Glycoprotein 21 Transmembrane Subunit for Induction of Native Protein Reactive Neutralizing Antibodies. J. Biol. Chem. 279: 24141-24151 [Abstract] [Full Text]  
• Ward, M., Lin, C., Victoria, D. C., Fox, B. P., Fox, J. A., Wong, D. L., Meerman, H. J., Pucci, J. P., Fong, R. B., Heng, M. H., Tsurushita, N., Gieswein, C., Park, M., Wang, H. (2004). Characterization of Humanized Antibodies Secreted by Aspergillus niger. Appl. Environ. Microbiol. 70: 2567-2576 [Abstract] [Full Text]  
• Benoit, V., Chariot, A., Delacroix, L., Deregowski, V., Jacobs, N., Merville, M.-P., Bours, V. (2004). Caspase-8-Dependent HER-2 Cleavage in Response to Tumor Necrosis Factor {alpha} Stimulation Is Counteracted by Nuclear Factor {kappa}B through c-FLIP-L Expression. Cancer Res. 64: 2684-2691 [Abstract] [Full Text]  
• Gensler, M., Buschbeck, M., Ullrich, A. (2004). Negative Regulation of HER2 Signaling by the PEST-type Protein-tyrosine Phosphatase BDP1. J. Biol. Chem. 279: 12110-12116 [Abstract] [Full Text]  
• Argiris, A., Wang, C.-X., Whalen, S. G., DiGiovanna, M. P. (2004). Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin). Clin. Cancer Res. 10: 1409-1420 [Abstract] [Full Text]  
• Perez, E. A., Rodeheffer, R. (2004). Clinical Cardiac Tolerability of Trastuzumab. JCO 22: 322-329 [Abstract] [Full Text]  
• Wolpoe, M. E., Lutz, E. R., Ercolini, A. M., Murata, S., Ivie, S. E., Garrett, E. S., Emens, L. A., Jaffee, E. M., Reilly, R. T. (2003). HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice. J. Immunol. 171: 2161-2169 [Abstract] [Full Text]  
• Barbacci, E. G., Pustilnik, L. R., Rossi, A. M. K., Emerson, E., Miller, P. E., Boscoe, B. P., Cox, E. D., Iwata, K. K., Jani, J. P., Provoncha, K., Kath, J. C., Liu, Z., Moyer, J. D. (2003). The Biological and Biochemical Effects of CP-654577, a Selective erbB2 Kinase Inhibitor, on Human Breast Cancer Cells. Cancer Res. 63: 4450-4459 [Abstract] [Full Text]  
• Repka, T., Chiorean, E. G., Gay, J., Herwig, K. E., Kohl, V. K., Yee, D., Miller, J. S. (2003). Trastuzumab and Interleukin-2 in HER2-positive Metastatic Breast Cancer: A Pilot Study. Clin. Cancer Res. 9: 2440-2446 [Abstract] [Full Text]  
• Miller, K., Meng, G., Liu, J., Hurst, A., Hsei, V., Wong, W.-L., Ekert, R., Lawrence, D., Sherwood, S., DeForge, L., Gaudreault, J., Keller, G., Sliwkowski, M., Ashkenazi, A., Presta, L. (2003). Design, Construction, and In Vitro Analyses of Multivalent Antibodies. J. Immunol. 170: 4854-4861 [Abstract] [Full Text]  
• Dakappagari, N. K., Pyles, J., Parihar, R., Carson, W. E., Young, D. C., Kaumaya, P. T. P. (2003). A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses. J. Immunol. 170: 4242-4253 [Abstract] [Full Text]  
• Sachdev, D., Li, S.-L., Hartell, J. S., Fujita-Yamaguchi, Y., Miller, J. S., Yee, D. (2003). A Chimeric Humanized Single-Chain Antibody against the Type I Insulin-like Growth Factor (IGF) Receptor Renders Breast Cancer Cells Refractory to the Mitogenic Effects of IGF-I. Cancer Res. 63: 627-635 [Abstract] [Full Text]  
• Itoh, K., Inoue, K., Tezuka, T., Tada, H., Hashimoto, Y., Masuko, T., Suzuki, T. (2003). Molecular Structural and Functional Characterization of Tumor Suppressive Anti-ErbB-2 Monoclonal Antibody by Phage Display System. J Biochem 133: 239-245 [Abstract] [Full Text]  
• Talukder, A. H., Bagheri-Yarmand, R., Williams, R. R. E., Ragoussis, J., Kumar, R., Raz, A. (2002). Antihuman Epidermal Growth Factor Receptor 2 Antibody Herceptin Inhibits Autocrine Motility Factor (AMF) Expression and Potentiates Antitumor Effects of AMF Inhibitors. Clin. Cancer Res. 8: 3285-3289 [Abstract] [Full Text]  
• Mendelsohn, J. (2002). Targeting the Epidermal Growth Factor Receptor for Cancer Therapy. JCO 20: 1s-13 [Full Text]  
• Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., Presta, L. G. (2002). Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human Fcgamma RIII and Antibody-dependent Cellular Toxicity. J. Biol. Chem. 277: 26733-26740 [Abstract] [Full Text]  
• Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., Seelig, S., Arteaga, C. L. (2002). Herceptin-induced Inhibition of Phosphatidylinositol-3 Kinase and Akt Is Required for Antibody-mediated Effects on p27, Cyclin D1, and Antitumor Action. Cancer Res. 62: 4132-4141 [Abstract] [Full Text]  
• Motoyama, A. B., Hynes, N. E., Lane, H. A. (2002). The Efficacy of ErbB Receptor-targeted Anticancer Therapeutics Is Influenced by the Availability of Epidermal Growth Factor-related Peptides. Cancer Res. 62: 3151-3158 [Abstract] [Full Text]  
• Frankel, A. E. (2002). New HER2-directed Therapies for Breast Cancer.: Commentary re: C. I. Spiridon et al., Targeting Multiple Her-2 Epitopes with Monoclonal Antibodies Results in Improved Antigrowth Activity. Clin. Cancer Res., 8: 1720-1730, 2002.. Clin. Cancer Res. 8: 1699-1701 [Full Text]  
• De Lorenzo, C., Palmer, D. B., Piccoli, R., Ritter, M. A., D'Alessio, G. (2002). A New Human Antitumor Immunoreagent Specific for ErbB2. Clin. Cancer Res. 8: 1710-1719 [Abstract] [Full Text]  
• Baselga, J. (2002). Targeting the Epidermal Growth Factor Receptor With Tyrosine Kinase Inhibitors: Small Molecules, Big Hopes. JCO 20: 2217-2219 [Full Text]  
• Pero, S. C., Oligino, L., Daly, R. J., Soden, A. L., Liu, C., Roller, P. P., Li, P., Krag, D. N. (2002). Identification of Novel Non-phosphorylated Ligands, Which Bind Selectively to the SH2 Domain of Grb7. J. Biol. Chem. 277: 11918-11926 [Abstract] [Full Text]  
• Chambers, C., Dimaculangan, D. M., Grindrod, K., Hanson, J., Pataky, F., Vu, T. T. (2002). Clinical effectiveness of trastuzumab: early experience. J Oncol Pharm Pract 8: 19-25 [Abstract]  
• Waelti, E., Wegmann, N., Schwaninger, R., Wetterwald, A., Wingenfeld, C., Rothen-Rutishauser, B., Gimmi, C. D. (2002). Targeting HER-2/neu with Antirat Neu Virosomes for Cancer Therapy. Cancer Res. 62: 437-444 [Abstract] [Full Text]  
• Albanell, J., Baselga, J. (2001). Unraveling Resistance to Trastuzumab (Herceptin): Insulin-Like Growth Factor-I Receptor, a New Suspect. JNCI J Natl Cancer Inst 93: 1830-1832 [Full Text]  
• Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., Pollak, M. (2001). Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin). JNCI J Natl Cancer Inst 93: 1852-1857 [Abstract] [Full Text]  
• Rusnak, D. W., Lackey, K., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., Gilmer, T. M. (2001). The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo. Molecular Cancer Therapeutics 1: 85-94 [Abstract] [Full Text]  
• Ohta, M., Tokuda, Y., Suzuki, Y., Kubota, M., Watanabe, T., Fujii, H., Sasaki, Y., Niwa, T., Makuuchi, H., Tajima, T. (2001). A Case with HER2-overexpressing Breast Cancer Completely Responded to Humanized anti-HER2 Monoclonal Antibody. Jpn J Clin Oncol 31: 553-556 [Abstract] [Full Text]  
• Rusnak, D. W., Affleck, K., Cockerill, S. G., Stubberfield, C., Harris, R., Page, M., Smith, K. J., Guntrip, S. B., Carter, M. C., Shaw, R. J., Jowett, A., Stables, J., Topley, P., Wood, E. R., Brignola, P. S., Kadwell, S. H., Reep, B. R., Mullin, R. J., Alligood, K. J., Keith, B. R., Crosby, R. M., Murray, D. M., Knight, W. B., Gilmer, T. M., Lackey, K. (2001). The Characterization of Novel, Dual ErbB-2/EGFR, Tyrosine Kinase Inhibitors: Potential Therapy for Cancer. Cancer Res. 61: 7196-7203 [Abstract] [Full Text]  
• Cuello, M., Ettenberg, S. A., Clark, A. S., Keane, M. M., Posner, R. H., Nau, M. M., Dennis, P. A., Lipkowitz, S. (2001). Down-Regulation of the erbB-2 Receptor by Trastuzumab (Herceptin) Enhances Tumor Necrosis Factor-related Apoptosis-inducing Ligand-mediated Apoptosis in Breast and Ovarian Cancer Cell Lines that Overexpress erbB-2. Cancer Res. 61: 4892-4900 [Abstract] [Full Text]  
• Yamauchi, H., Stearns, V., Hayes, D. F. (2001). When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer. JCO 19: 2334-2356 [Abstract] [Full Text]  
• Yip, Y. L., Smith, G., Koch, J., Dubel, S., Ward, R. L. (2001). Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design. J. Immunol. 166: 5271-5278 [Abstract] [Full Text]  
• Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., Norton, L. (2001). Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. NEJM 344: 783-792 [Abstract] [Full Text]  
• Hellström, I., Goodman, G., Pullman, J., Yang, Y., Hellström, K. E. (2001). Overexpression of HER-2 in Ovarian Carcinomas. Cancer Res. 61: 2420-2423 [Abstract] [Full Text]  
• Lebeau, A., Deimling, D., Kaltz, C., Sendelhofert, A., Iff, A., Luthardt, B., Untch, M., Lohrs, U. (2001). HER-2/neu Analysis in Archival Tissue Samples of Human Breast Cancer: Comparison of Immunohistochemistry and Fluorescence In Situ Hybridization. JCO 19: 354-363 [Abstract] [Full Text]  
• Ward, R. L., Packham, D., Smythe, A. M., Murray, J., Anderson-Stewart, P., Kitchen, N., Muirhead, R., Phillips, P., Gray, P., Bigg-Wither, G., Prabakaran, K., Freund, J., Fullham, M., Rule, M., Dalley, D., Meagher, A., Hawkins, N. J., Smith, G. M. (2000). Phase I Clinical Trial of the Chimeric Monoclonal Antibody (c30.6) in Patients with Metastatic Colorectal Cancer. Clin. Cancer Res. 6: 4674-4683 [Abstract] [Full Text]  
• Mendelsohn, J. (2000). Use of an Antibody to Target Geldanamycin. JNCI J Natl Cancer Inst 92: 1549-1551 [Full Text]  
• Le, X.-F., Vadlamudi, R., McWatters, A., Bae, D. S., Mills, G. B., Kumar, R., Bast, R. C. Jr. (2000). Differential Signaling by an Anti-p185HER2 Antibody and Heregulin. Cancer Res. 60: 3522-3531 [Abstract] [Full Text]  
• Dakappagari, N. K., Douglas, D. B., Triozzi, P. L., Stevens, V. C., Kaumaya, P. T. P. (2000). Prevention of Mammary Tumors with a Chimeric HER-2 B-cell Epitope Peptide Vaccine. Cancer Res. 60: 3782-3789 [Abstract] [Full Text]  
• Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., Hynes, N. E. (2000). ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency. Mol. Cell. Biol. 20: 3210-3223 [Abstract] [Full Text]  
• Mendelsohn, J. (2000). Blockade of Receptors for Growth Factors: An Anticancer Therapy -- The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture. Clin. Cancer Res. 6: 747-753 [Full Text]  
• Roh, H., Pippin, J., Drebin, J. A. (2000). Down-Regulation of HER2/neu Expression Induces Apoptosis in Human Cancer Cells That Overexpress HER2/neu. Cancer Res. 60: 560-565 [Abstract] [Full Text]  
• Le, X.-F., McWatters, A., Wiener, J., Wu, J.-Y., Mills, G. B., Bast, R. C. Jr. (2000). Anti-HER2 Antibody and Heregulin Suppress Growth of HER2-Overexpressing Human Breast Cancer Cells through Different Mechanisms. Clin. Cancer Res. 6: 260-270 [Abstract] [Full Text]  
• Agus, D. B., Scher, H. I., Higgins, B., Fox, W. D., Heller, G., Fazzari, M., Cordon-Cardo, C., Golde, D. W. (1999). Response of Prostate Cancer to Anti-Her-2/neu Antibody in Androgen-dependent and -independent Human Xenograft Models. Cancer Res. 59: 4761-4764 [Abstract] [Full Text]  
• Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., Slamon, D. J. (1999). Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. JCO 17: 2639-2639 [Abstract] [Full Text]  
• Marches, R., Hsueh, R., Uhr, J. W. (1999). Cancer dormancy and cell signaling: Induction of p21waf1 initiated by membrane IgM engagement increases survival of B lymphoma cells. Proc. Natl. Acad. Sci. USA 96: 8711-8715 [Abstract] [Full Text]  
• Olayioye, M. A., Graus-Porta, D., Beerli, R. R., Rohrer, J., Gay, B., Hynes, N. E. (1998). ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner. Mol. Cell. Biol. 18: 5042-5051 [Abstract] [Full Text]  
• Reese, D. M., Slamon, D. J. (1997). HER-2/neu Signal Transduction in Human Breast and Ovarian Cancer. Stem Cells 15: 1-8 [Abstract] [Full Text]  
• Holmes, W. E., Sliwkowski, M. X., Akita, R. W., Henzel, W. J., Lee, J., Park, J. W., Yansura, D., Abadi, N., Raab, H., Lewis, G. D., Shepard, H. M., Kuang, W.-J., Wood, W. l., Goeddel, D. V., Vandlen, R. L. (1992). Identification of Heregulin, a Specific Activator of p185erbB2. Science 256: 1205-1210 [Abstract]  
• Aaronson, S. (1991). Growth factors and cancer. Science 254: 1146-1153 [Abstract]  
• Lupu, R, Colomer, R, Zugmaier, G, Sarup, J, Shepard, M, Slamon, D, Lippman, M. (1990). Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science 249: 1552-1555 [Abstract]  
• Talukder, A. H., Jorgensen, H. F., Mandal, M., Mishra, S. K., Vadlamudi, R. K, Clark, B. F. C., Mendelsohn, J., Kumar, R. (2001). Regulation of Elongation Factor-1alpha Expression by Growth Factors and Anti-receptor Blocking Antibodies. J. Biol. Chem. 276: 5636-5642 [Abstract] [Full Text]  
• Mandal, M., Vadlamudi, R., Nguyen, D., Wang, R.-A., Costa, L., Bagheri-Yarmand, R., Mendelsohn, J., Kumar, R. (2001). Growth Factors Regulate Heterogeneous Nuclear Ribonucleoprotein K Expression and Function. J. Biol. Chem. 276: 9699-9704 [Abstract] [Full Text]  
• Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., Fox, J. A., Presta, L. G. (2001). High Resolution Mapping of the Binding Site on Human IgG1 for Fcgamma RI, Fcgamma RII, Fcgamma RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fcgamma R. J. Biol. Chem. 276: 6591-6604 [Abstract] [Full Text]  
• Beerli, R. R., Dreier, B., Barbas, C. F. III (2000). Positive and negative regulation of endogenous genes by designed transcription factors. Proc. Natl. Acad. Sci. USA 97: 1495-1500 [Abstract] [Full Text]  
• Zhang, H.-T., Kacharmina, J. E., Miyashiro, K., Greene, M. I., Eberwine, J. (2001). Protein quantification from complex protein mixtures using a proteomics methodology with single-cell resolution. Proc. Natl. Acad. Sci. USA 98: 5497-5502 [Abstract] [Full Text]